BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 30463570)

  • 1. LncRNA XIST/miR-34a axis modulates the cell proliferation and tumor growth of thyroid cancer through MET-PI3K-AKT signaling.
    Liu H; Deng H; Zhao Y; Li C; Liang Y
    J Exp Clin Cancer Res; 2018 Nov; 37(1):279. PubMed ID: 30463570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MiR-34a targets GAS1 to promote cell proliferation and inhibit apoptosis in papillary thyroid carcinoma via PI3K/Akt/Bad pathway.
    Ma Y; Qin H; Cui Y
    Biochem Biophys Res Commun; 2013 Nov; 441(4):958-63. PubMed ID: 24220341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Knockdown of long non-coding RNA HOTAIR inhibits cisplatin resistance of gastric cancer cells through inhibiting the PI3K/Akt and Wnt/β-catenin signaling pathways by up-regulating miR-34a.
    Cheng C; Qin Y; Zhi Q; Wang J; Qin C
    Int J Biol Macromol; 2018 Feb; 107(Pt B):2620-2629. PubMed ID: 29080815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Downregulation of NEAT1 reverses the radioactive iodine resistance of papillary thyroid carcinoma cell via miR-101-3p/FN1/PI3K-AKT signaling pathway.
    Liu C; Feng Z; Chen T; Lv J; Liu P; Jia L; Zhu J; Chen F; Yang C; Deng Z
    Cell Cycle; 2019 Jan; 18(2):167-203. PubMed ID: 30596336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long non-coding RNA-SNHG7 acts as a target of miR-34a to increase GALNT7 level and regulate PI3K/Akt/mTOR pathway in colorectal cancer progression.
    Li Y; Zeng C; Hu J; Pan Y; Shan Y; Liu B; Jia L
    J Hematol Oncol; 2018 Jul; 11(1):89. PubMed ID: 29970122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LncRNA-XIST/microRNA-126 sponge mediates cell proliferation and glucose metabolism through the IRS1/PI3K/Akt pathway in glioma.
    Cheng Z; Luo C; Guo Z
    J Cell Biochem; 2020 Mar; 121(3):2170-2183. PubMed ID: 31680298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiR-1246 regulates the PI3K/AKT signaling pathway by targeting PIK3AP1 and inhibits thyroid cancer cell proliferation and tumor growth.
    Li J; Zhang Z; Hu J; Wan X; Huang W; Zhang H; Jiang N
    Mol Cell Biochem; 2022 Mar; 477(3):649-661. PubMed ID: 34870753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. lncRNAPVT1 targets miR-152 to enhance chemoresistance of osteosarcoma to gemcitabine through activating c-MET/PI3K/AKT pathway.
    Sun ZY; Jian YK; Zhu HY; Li B
    Pathol Res Pract; 2019 Mar; 215(3):555-563. PubMed ID: 30661902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LncRNA XIST Promotes Migration and Invasion of Papillary Thyroid Cancer Cell by Modulating MiR-101-3p/CLDN1 Axis.
    Du YL; Liang Y; Cao Y; Liu L; Li J; Shi GQ
    Biochem Genet; 2021 Apr; 59(2):437-452. PubMed ID: 33057875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. STAT3-induced upregulation of lncRNA ABHD11-AS1 promotes tumour progression in papillary thyroid carcinoma by regulating miR-1301-3p/STAT3 axis and PI3K/AKT signalling pathway.
    Wen J; Wang H; Dong T; Gan P; Fang H; Wu S; Li J; Zhang Y; Du R; Zhu Q
    Cell Prolif; 2019 Mar; 52(2):e12569. PubMed ID: 30657221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long Coding RNA XIST Contributes to Neuronal Apoptosis through the Downregulation of AKT Phosphorylation and Is Negatively Regulated by miR-494 in Rat Spinal Cord Injury.
    Gu S; Xie R; Liu X; Shou J; Gu W; Che X
    Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28368292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-34A inhibits the growth, invasion and metastasis of gastric cancer by targeting PDGFR and MET expression.
    Peng Y; Guo JJ; Liu YM; Wu XL
    Biosci Rep; 2014 Jun; 34(3):. PubMed ID: 24837198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LncRNA MIR31HG functions as a ceRNA to regulate c-Met function by sponging miR-34a in esophageal squamous cell carcinoma.
    Chu J; Jia J; Yang L; Qu Y; Yin H; Wan J; He F
    Biomed Pharmacother; 2020 Aug; 128():110313. PubMed ID: 32502839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Roles of the SNHG7/microRNA‑9‑5p/DPP4 ceRNA network in the growth and
    Chen W; Yu J; Xie R; Zhou T; Xiong C; Zhang S; Zhong M
    Oncol Rep; 2021 Apr; 45(4):. PubMed ID: 33649840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circ_0079558 promotes papillary thyroid cancer progression by binding to miR-26b-5p to activate MET/AKT signaling.
    Zheng H; Fu Q; Ma K; Shi S; Fu Y
    Endocr J; 2021 Nov; 68(11):1247-1266. PubMed ID: 34565758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel lncRNA n384546 promotes thyroid papillary cancer progression and metastasis by acting as a competing endogenous RNA of miR-145-5p to regulate AKT3.
    Feng J; Zhou Q; Yi H; Ma S; Li D; Xu Y; Wang J; Yin S
    Cell Death Dis; 2019 Jun; 10(6):433. PubMed ID: 31160577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long non-coding RNA TTN-AS1 facilitates tumorigenesis of papillary thyroid cancer through modulating the miR-153-3p/ZNRF2 axis.
    Cui Z; Luo Z; Lin Z; Shi L; Hong Y; Yan C
    J Gene Med; 2019 May; 21(5):e3083. PubMed ID: 30811764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-146b promotes PI3K/AKT pathway hyperactivation and thyroid cancer progression by targeting PTEN.
    Ramírez-Moya J; Wert-Lamas L; Santisteban P
    Oncogene; 2018 Jun; 37(25):3369-3383. PubMed ID: 29353884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Downregulation of lncRNA ZEB1-AS1 Represses Cell Proliferation, Migration, and Invasion Through Mediating PI3K/AKT/mTOR Signaling by miR-342-3p/CUL4B Axis in Prostate Cancer.
    Ma T; Chen H; Wang P; Yang N; Bao J
    Cancer Biother Radiopharm; 2020 Nov; 35(9):661-672. PubMed ID: 32275162
    [No Abstract]   [Full Text] [Related]  

  • 20. Antitumor activity of miR-34a in peritoneal mesothelioma relies on c-MET and AXL inhibition: persistent activation of ERK and AKT signaling as a possible cytoprotective mechanism.
    El Bezawy R; De Cesare M; Pennati M; Deraco M; Gandellini P; Zuco V; Zaffaroni N
    J Hematol Oncol; 2017 Jan; 10(1):19. PubMed ID: 28100259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.